CO3_NAJNA
ID CO3_NAJNA Reviewed; 1651 AA.
AC Q01833;
DT 01-JUL-1993, integrated into UniProtKB/Swiss-Prot.
DT 01-JUL-1993, sequence version 1.
DT 03-AUG-2022, entry version 105.
DE RecName: Full=Complement C3;
DE Contains:
DE RecName: Full=Complement C3 beta chain;
DE Contains:
DE RecName: Full=Complement C3 alpha chain;
DE Contains:
DE RecName: Full=C3a anaphylatoxin;
DE Contains:
DE RecName: Full=Complement C3b alpha' chain;
DE Contains:
DE RecName: Full=Complement C3f fragment;
DE Flags: Precursor;
GN Name=C3;
OS Naja naja (Indian cobra).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Lepidosauria; Squamata; Bifurcata; Unidentata; Episquamata; Toxicofera;
OC Serpentes; Colubroidea; Elapidae; Elapinae; Naja.
OX NCBI_TaxID=35670;
RN [1]
RP NUCLEOTIDE SEQUENCE [MRNA].
RC TISSUE=Liver;
RX PubMed=1431125;
RA Fritzinger D.C., Connelly M., Petrella E.C., Bredehorst R., Vogel C.-W.;
RT "Primary structure of cobra complement component C3.";
RL J. Immunol. 149:3554-3562(1992).
CC -!- FUNCTION: C3 plays a central role in the activation of the complement
CC system. Its processing by C3 convertase is the central reaction in both
CC classical and alternative complement pathways. After activation C3b can
CC bind covalently, via its reactive thioester, to cell surface
CC carbohydrates or immune aggregates.
CC -!- FUNCTION: Derived from proteolytic degradation of complement C3, C3a
CC anaphylatoxin is a mediator of local inflammatory process. It induces
CC the contraction of smooth muscle, increases vascular permeability and
CC causes histamine release from mast cells and basophilic leukocytes.
CC -!- SUBUNIT: C3 precursor is first processed by the removal of 4 Arg
CC residues, forming two chains, beta and alpha, linked by a disulfide
CC bond. C3 convertase activates C3 by cleaving the alpha chain, releasing
CC C3a anaphylatoxin and generating C3b (beta chain + alpha' chain) (By
CC similarity). {ECO:0000250}.
CC -!- SUBCELLULAR LOCATION: Secreted.
CC ---------------------------------------------------------------------------
CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC ---------------------------------------------------------------------------
DR EMBL; L02365; AAA49385.1; -; mRNA.
DR AlphaFoldDB; Q01833; -.
DR SMR; Q01833; -.
DR MEROPS; I39.950; -.
DR PRIDE; Q01833; -.
DR Proteomes; UP000694559; Unplaced.
DR GO; GO:0005615; C:extracellular space; IEA:InterPro.
DR GO; GO:0004866; F:endopeptidase inhibitor activity; IEA:InterPro.
DR GO; GO:0006957; P:complement activation, alternative pathway; IEA:UniProtKB-KW.
DR GO; GO:0006958; P:complement activation, classical pathway; IEA:UniProtKB-KW.
DR GO; GO:0006954; P:inflammatory response; IEA:UniProtKB-KW.
DR CDD; cd00017; ANATO; 1.
DR CDD; cd03583; NTR_complement_C3; 1.
DR Gene3D; 2.40.50.120; -; 1.
DR Gene3D; 2.60.40.10; -; 2.
DR Gene3D; 2.60.40.690; -; 1.
DR InterPro; IPR009048; A-macroglobulin_rcpt-bd.
DR InterPro; IPR036595; A-macroglobulin_rcpt-bd_sf.
DR InterPro; IPR011625; A2M_N_BRD.
DR InterPro; IPR011626; Alpha-macroglobulin_TED.
DR InterPro; IPR000020; Anaphylatoxin/fibulin.
DR InterPro; IPR018081; Anaphylatoxin_comp_syst.
DR InterPro; IPR001840; Anaphylatoxn_comp_syst_dom.
DR InterPro; IPR041425; C3/4/5_MG1.
DR InterPro; IPR035711; Complement_C3-like.
DR InterPro; IPR013783; Ig-like_fold.
DR InterPro; IPR001599; Macroglobln_a2.
DR InterPro; IPR019742; MacrogloblnA2_CS.
DR InterPro; IPR002890; MG2.
DR InterPro; IPR041555; MG3.
DR InterPro; IPR040839; MG4.
DR InterPro; IPR001134; Netrin_domain.
DR InterPro; IPR018933; Netrin_module_non-TIMP.
DR InterPro; IPR035815; NTR_complement_C3.
DR InterPro; IPR008930; Terpenoid_cyclase/PrenylTrfase.
DR InterPro; IPR008993; TIMP-like_OB-fold.
DR PANTHER; PTHR11412:SF81; PTHR11412:SF81; 1.
DR Pfam; PF00207; A2M; 1.
DR Pfam; PF07703; A2M_BRD; 1.
DR Pfam; PF07677; A2M_recep; 1.
DR Pfam; PF01821; ANATO; 1.
DR Pfam; PF17790; MG1; 1.
DR Pfam; PF01835; MG2; 1.
DR Pfam; PF17791; MG3; 1.
DR Pfam; PF17789; MG4; 1.
DR Pfam; PF01759; NTR; 1.
DR Pfam; PF07678; TED_complement; 1.
DR PRINTS; PR00004; ANAPHYLATOXN.
DR SMART; SM01360; A2M; 1.
DR SMART; SM01359; A2M_N_2; 1.
DR SMART; SM01361; A2M_recep; 1.
DR SMART; SM00104; ANATO; 1.
DR SMART; SM00643; C345C; 1.
DR SUPFAM; SSF47686; SSF47686; 1.
DR SUPFAM; SSF48239; SSF48239; 1.
DR SUPFAM; SSF49410; SSF49410; 1.
DR SUPFAM; SSF50242; SSF50242; 1.
DR PROSITE; PS00477; ALPHA_2_MACROGLOBULIN; 1.
DR PROSITE; PS01177; ANAPHYLATOXIN_1; 1.
DR PROSITE; PS01178; ANAPHYLATOXIN_2; 1.
DR PROSITE; PS50189; NTR; 1.
PE 2: Evidence at transcript level;
KW Complement alternate pathway; Complement pathway; Disulfide bond; Immunity;
KW Inflammatory response; Innate immunity; Reference proteome; Secreted;
KW Signal; Thioester bond.
FT SIGNAL 1..22
FT /evidence="ECO:0000250"
FT CHAIN 23..1651
FT /note="Complement C3"
FT /id="PRO_0000288818"
FT CHAIN 23..655
FT /note="Complement C3 beta chain"
FT /id="PRO_0000288819"
FT CHAIN 661..1651
FT /note="Complement C3 alpha chain"
FT /id="PRO_0000288820"
FT PEPTIDE 661..738
FT /note="C3a anaphylatoxin"
FT /evidence="ECO:0000250"
FT /id="PRO_0000288821"
FT CHAIN 739..1651
FT /note="Complement C3b alpha' chain"
FT /evidence="ECO:0000250"
FT /id="PRO_0000288822"
FT PEPTIDE 1291..1307
FT /note="Complement C3f fragment"
FT /evidence="ECO:0000250"
FT /id="PRO_0000288823"
FT DOMAIN 683..718
FT /note="Anaphylatoxin-like"
FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00022"
FT DOMAIN 1506..1649
FT /note="NTR"
FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00295"
FT REGION 660..738
FT /note="C3a-like domain"
FT REGION 991..1269
FT /note="C3d-like domain"
FT REGION 1412..1444
FT /note="Properdin-binding"
FT /evidence="ECO:0000250"
FT SITE 738..739
FT /note="Cleavage; by C3 convertase"
FT SITE 1290..1291
FT /note="Cleavage; by factor I"
FT /evidence="ECO:0000250"
FT SITE 1307..1308
FT /note="Cleavage; by factor I"
FT /evidence="ECO:0000250"
FT DISULFID 546..807
FT /note="Interchain (between beta and alpha chains)"
FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00022,
FT ECO:0000255|PROSITE-ProRule:PRU00295"
FT DISULFID 615..650
FT /evidence="ECO:0000250"
FT DISULFID 683..710
FT /evidence="ECO:0000250"
FT DISULFID 684..717
FT /evidence="ECO:0000250"
FT DISULFID 697..718
FT /evidence="ECO:0000250"
FT DISULFID 863..1501
FT /evidence="ECO:0000250"
FT DISULFID 1091..1147
FT /evidence="ECO:0000250"
FT DISULFID 1346..1477
FT /evidence="ECO:0000250"
FT DISULFID 1377..1446
FT /evidence="ECO:0000250"
FT DISULFID 1494..1499
FT /evidence="ECO:0000250"
FT DISULFID 1506..1578
FT /evidence="ECO:0000250"
FT DISULFID 1525..1649
FT /evidence="ECO:0000250"
FT DISULFID 1625..1634
FT /evidence="ECO:0000250"
FT CROSSLNK 999..1002
FT /note="Isoglutamyl cysteine thioester (Cys-Gln)"
FT /evidence="ECO:0000250"
SQ SEQUENCE 1651 AA; 184927 MW; 66F91BD8F4A935F7 CRC64;
MEGMALYLVA ALLIGFPGSS HGALYTLITP AVLRTDTEEQ ILVEAHGDST PKSLDIFVHD
FPRKQKTLFQ SRVDMNQAGS MFVTPTIKVP AKELNKDSKQ NQYVVVKVTG PQVALEKVVL
LSYQSGFVFI QTDKGIYTPG SPVRYRVFSV DHNMHRMDKT VIVEFQTPEG IVVSSKPVNP
SGSIRPYNLP ELVSFGTWKA VAKYEHSPEE SYTAYFDVRE YVLPSFEVRL QPSDKFLYID
GNKNFHVSIT ARYLYGKKVE GVAFVVFGVK IDDAKKSIPD SLTRIPIIDG DGEATLKRDT
LRSRFQDLNQ LVGHTLYVSV TVITESGSDM VVTEQGGIHI VTSPYQIYFT KTPKYFKPGM
PYELTVYVTN PDGSPAAHVP VVSEAIHSEG TTLSDGTAKL ILNTPLNIQS LPITVRTNHG
DLPRERQAIK SMTATAYQTQ GGSENYLHVA ITSTEIKPGD NLPVNFNVRG NANSLNQIKY
FTYLILNKGK IFKVGRQPRR DGQNLVTMNL HITPDLIPSF RFVAYYQVGN NEIVADSVWV
DVKDTCMGTL VVKGASSRDD RIQKPGAAMK IKLEGDPGAR VGLVAVDKAV YVLNDKYKIS
QAKIWDTIEK SDFGCTAGSG QNNLGVFEDA GLALTTSTNL NTKQRSAAKC PQPANRRRRS
SVLLLDSKAS KAAQFQDQGL RKCCEDGMHE NPMGYTCEKR AKYIQEGDAC KAAFLECCHY
IKGIRDENQR ESELFLARSD FEDELFGDDN IISRSDFPES WLWLTEELTG EPNNQGISSK
TVPFYLRDSI TTWELLAVGL SPTKGICVAE PYEITVMKDF FIDLRLPYSV VKNEQVEIRA
ILYNYADEDI YVRVELIYNP AFCSASTEGQ RYRQQFPIKA LSSRAVPFVI VPLEQGLHDV
EVIASVRGEL ASDGVRKKLK VVPEGERKNI VTIIELDPSV KGVGGTQELT VIANKLDDKV
PDTEVETRIS VLGDPVAQII ENSIDGSKLN HLIITPSGCG EQNMITMTPS VIATYYLDAT
GQWENLGVDR RTEAIKQIMT GYAQQMVYKK ADHSYAAFTN RASSSWLTAY VVKVLAMASN
MVKDISHEII CGGVKWLILN RQQPDGVFKE NAPVIHGEML GGTKGAEPEA SLTAFIVTAL
LESRSVCKEQ INILDSSINK ATDYLLKKYE KLQRPYTTAL TAYALAAADR LNDDRVLMAA
STGRNRWEEY NARTHNIEGT SYALLALLKM KKFAEVGPVV RWLIDQKYYG GTYGQTQATV
MVFQALAEYE IQMPTHQDLN LDISIKLPER EVPERYSIND RNAVQARTVE TKLNEDFTVS
ASGDGKATMT ILTVYNAQLR EDANVCNKFH LDVSVENVEL NLKQAKGGKA ALRLKICTRY
LGEVDSTMTI IDISMLTGFF PDAEDLKRLS NGVDRYISKF EIDNNMAQKG TVVIYLDKVS
HSEDECLHFK IHKHFEVGFI QPGSVKVYSY YNLDEQCTKF YHPDKETGLL NKICHGNICR
CAEETCSLLN QQKKIDLQLR IQKACAQNVD YVYKTKLLRI EEKDGNDIYF MDVLEVIKGG
TDRNAQAKAR QYVSQRKCQE ALNLKLDNDY LIWGLSSDLW PMKDDISYLI TKNTWIERWP
NEDECQDEEF QNLCDDFAQL SNTLTIFGCP T